Abstract
In March 2024 Clade 2.3.4.4b H5N1 highly pathogenic avian influenza virus (HPAIV) was detected in dairy cattle in the US and it was discovered that the virus could be detected in raw milk. Although affected cow’s milk is diverted from human consumption and current pasteurization requirements are expected to reduce or eliminate HPAIV from the milk supply, a study was conducted to characterize whether the virus could be detected by quantitative real-time RT-PCR (qrRT-PCR) in pasteurized retail dairy products and if detected, to determine whether the virus was viable. From April 18 to 22, 2024 a total of 297 samples of Grade A pasteurized retail milk products (23 product types) were collected from 17 US states and represented products from 132 processors in 38 states. Viral RNA was detected in 60 samples (20.2%) with titer equivalents of up to 5.4log10 50% egg infectious doses (EID50) per ml, with a mean and median of 3.0log10/ml and 2.9log10 /ml respectively. Samples that were positive for type A influenza by qrRT-PCR were confirmed to be clade 2.3.4.4 H5 HPAIV by qrRT-PCR. No infectious virus was detected in any of the qrRT-PCR positive samples in embryonating chicken eggs. Further studies are needed to monitor the milk supply but these results provide evidence that infectious virus did not enter the US pasteurized milk supply before control measures for HPAIV were implemented in dairy cattle.
Importance Highly pathogenic avian influenza virus (HPAIV) infections in US dairy cattle were first confirmed in March 2024. Because the virus could be detected in raw milk a study was conducted to determine whether it had entered the retail food supply. Pasteurized dairy products were collected from 17 states in April 2024. Viral RNA was detected in 1 in 5 samples but infectious virus was not detected. This provides a snap-shot of HPAIV in milk products early in the event and reinforces that with numerous safety measures, infectious virus in milk is unlikely to enter the food supply.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the US Dept of Agriculture project # 6040-32000-081-00D and the US Food and Drug Administration project # pending.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript and supplemental data.
